Interleukin-2 (IL-2) administered intravenously as a single agent or together with lymphokine activated killer cells has been shown to have activity against a variety of tumours with the highest response rates recorded in patients with renal cell carcinoma and melanoma (21-35%, Rosenberg et al., 1989 ). The precise mechanism by which IL-2 causes tumour regression is uncertain but it may involve the activation of cellular immune mechanisms. In vivo IL-2 stimulates the proliferation of a variety of lymphoid cells including activated T cells, natural killer cells, lymphokine activated killer cells, B cells and macrophages (Gillis & Smith, 1977; Henny et al., 1981; Grimm et al., 1982; Waldmann et al., 1984; Malkovsky et al., 1987) . IL-2 is a powerful regulator of the immune system and although it is detectable in the serum of healthy controls and cancer patients (Lissoni et al., 1990) its main site of action is probably at a local level. Therefore, a more physiological approach to the administration of IL-2 might be to deliver it locally to sites where potentially tumoricidal lymphocytes may be concentrated. Such loco-regional therapy should also be associated with fewer systemic side effects. Continuous intralymphatic infusions over a period of days are not technically possible but a similar result could be achieved by the intra-arterial route. Patients with tumours of the head and neck were selected for this treatment approach as the arterial supply to these tumours is frequently accessible to cannulation. In addition these lesions are often easily biopsied and provide a unique opportunity to study the histopathological and immunohistochemical changes associated with the local delivery of varying concentations of IL-2.
We present the first stage of this programme which is a phase I dose escalation study of intra-arterial IL-2 administered by continuous infusion over a maximum of 10 days to patients with incurable squamous cell carcinoma of the head and neck. (Table I ). The first patient was treated for 5 days, patients 2-4 for 10 days with a 2 day break after 5 days and subsequently it was planned that all patients should receive continuous treatment for 10 days. However, the two patients treated at the highest dose level (3 x 107 iu day) required a 2 day break after 5 days of treatment because of systemic toxicity.
Materials and methods

Patients
The end point of the study was the development of systemic toxicity typical of intravenous interleukin-2 at standard dose which for most continuous infusion regimens is 18 x I06 iu m2 day. (Miller et al., 1981) .
Results
Patients treated at dose levels 1-3 did not experience any significant systemic side effecs (Tables II and III) and remained fully mobile and capable of self-care. However systemic toxicity typical of iv IL-2 at standard dose was seen at the highest dose level (level 4; 3 x I07 iu day). The two patients treated at this dose experienced anorexia, nausea, fever, fatigue, weight gain and transient abnormalities of liver function (grade 1). In addition, one of these patients became hypoalbuminaemic and experienced episodes of hypotension (grade 3) while the other complained of shortness of breath (grade 2) and dry desquamation of his skin (grade 2).
The commonest toxicities encountered were local: tumour pain, eight patients; facial oedema, eight patients; infection/ facial cellulitis, four patients. These side effects were not dose-related and resolved during the week following cessation of treatment. The four patients with signs of local cellulitis were treated with antibiotics although none had a positive blood culture. Two patients had haemorrhages from their iv day had partial responses and no response were seen at doses above this level.
Discussion
We have found that significant systemic side effects do not occur with intra-arterial IL-2 at doses of 3 x 106 iu day and below. At a dose of 3 x I07 iu day systemic toxicity is similar to that seen with standard intravenous regimens. Local complications were greater than expected particularly those of cellulitis, facial oedema and arterial thrombosis. The cellulitis and local oedema were not due to infection although we and others have reported an increased risk of infection associated with IL-2 therapy (Hartmann et al., 1989; Bock et al., 1990; Hardy et al., 1990) . Histological examination of post-treatment biopsies did not reveal any specific explanation for this complication (data not shown). Arterial thrombosis was a major problem during the early part of the study until patients were systemically anti-coagulated. There have been previous reports of local thrombus associated with intraarterial IL-2 (Klasa & Silver, 1989; Eggermont et al., 1990; Mavligit et al., 1990) and it has been suggested that this is due to direct damage to the vascular endothelium by IL-2 activated lymphocytes (Damle et al., 1987) , activation of the intrinsic system of coagulation (Fleischmann et al., 1991) or an increase in the coagulant properties of endothelium by IL-2-induced cytokines such as IL-1 and tumour necrosis factor (Cotran & Pober, 1989) . Phase II trials in patients with squamous cell carcinoma of the head and neck utilising perilymphatic injections have been performed but reported response rates vary widely, from 0-8% (Selvaggi et al., 1990; de Mulder et al., 1989) to 65% (Cortesina et al., 1991) . All these studies suggested that systemic toxicity is absent when this approach is employed, but at doses of 103 iu local swelling and pain occurred similar to that observed in our patients (Cortesina et al., 1991) . In these studies bolus doses were given and thus the tumour infiltrating lymphocytes were only intermittently exposed to IL-2. It is possible that continuous exposure to IL-2 might result in a greater anti-tumour effect.
Head and neck cancers are often easily accessible to biopsy and therefore a programme of locally infused IL-2 presents a unique opportunity to study the precise changes that take place within tumours as a result of prolonged exposure to both high and low local concentrations of IL-2. In addition, intra-arterial IL-2 studies have important implications for those groups who are studying targeted gene therapy. Unless continuous intra-tumoral infusions of IL-2 cause tumour regressions then it is unlikely that a strategy utilising IL-2 secreting tumour infiltrating lymphocytes will be of benefit. We suggest that groups currently working on targeted gene therapy study the effects of locally infused IL-2 before embarking on any clinical trials.
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